Cargando…

Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors

Multiple myeloma (MM) is a hematologic malignancy characterized by severely profound immune dysfunction. Therefore, the efficacy of drugs targeting the immune environments, such as immune checkpoint inhibitors (ICIs), is of high clinical importance. However, several clinical trials evaluating ICIs i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulikowska de Nałęcz, Anna, Ciszak, Lidia, Usnarska-Zubkiewicz, Lidia, Pawlak, Edyta, Frydecka, Irena, Szmyrka, Magdalena, Kosmaczewska, Agata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056286/ https://www.ncbi.nlm.nih.gov/pubmed/36982802 http://dx.doi.org/10.3390/ijms24065730

Ejemplares similares

Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients
por: Kulikowska de Nałęcz, Anna, et al.
Publicado: (2021)

Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody
por: Ciszak, Lidia, et al.
Publicado: (2015)

CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia
por: Ciszak, Lidia, et al.
Publicado: (2015)

Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients
por: Karabon, L., et al.
Publicado: (2020)

Dysregulated Expression of Both the Costimulatory CD28 and Inhibitory CTLA-4 Molecules in PB T Cells of Advanced Cervical Cancer Patients Suggests Systemic Immunosuppression Related to Disease Progression
por: Kosmaczewska, Agata, et al.
Publicado: (2011)

Exogenous IL-2 Controls the Balance in Th1, Th17, and Treg Cell Distribution in Patients with Progressive Rheumatoid Arthritis Treated with TNF-Alpha Inhibitors
por: Kosmaczewska, Agata, et al.
Publicado: (2014)

Alterations in Both the Activatory and Inhibitory Potential of Peripheral Blood CD4+ T Cells in Rheumatoid Arthritis Patients Correlate with Disease Progression
por: Kosmaczewska, Agata, et al.
Publicado: (2013)

Variations in Suppressor Molecule CTLA-4 Gene Are Related to Susceptibility to Multiple Myeloma in a Polish Population
por: Karabon, Lidia, et al.
Publicado: (2011)

Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement
por: Kosmaczewska, Agata, et al.
Publicado: (2013)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia
por: Frydecka, I, et al.
Publicado: (2004)

Imbalance in PB IL-17-Secreting and Regulatory Cells in Pars Planitis Is Associated with Dysregulation of IFN-γ-Secreting Cells, Especially in Patients with Clinical Complications
por: Kosmaczewska, Agata, et al.
Publicado: (2020)

CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
por: Pawlak-Adamska, Edyta, et al.
Publicado: (2016)

Erratum to: CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
por: Pawlak-Adamska, Edyta, et al.
Publicado: (2017)

P980: THE ROLE OF PLATELET AND ENDOTHELIAL MICROPARTICLES AND DOPPLER ULTRASOUND SCREENING IN THE ASSESSMENT OF THROMBOTIC READINESS IN MULTIPLE MYELOMA AND NON HODGKIN LYMPHOMA, PROSPECTIVE STUDY
por: Olszewska-Szopa, Magdalena, et al.
Publicado: (2023)

Ascites in the Course of Plasma Cell Myeloma Complicated by AL Amyloidosis
por: Debski, Jakub, et al.
Publicado: (2018)

A CT60G>A polymorphism in the CTLA-4 gene of the recipient may confer susceptibility to acute graft versus host disease after allogeneic hematopoietic stem cell transplantation
por: Karabon, Lidia, et al.
Publicado: (2015)

The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease
por: Frydecka, I, et al.
Publicado: (2001)

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
por: Le Mercier, Isabelle, et al.
Publicado: (2015)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
por: Qin, Shuang, et al.
Publicado: (2019)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia
por: Broglie, Larisa, et al.
Publicado: (2019)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
por: Gerdes, Lisa Ann, et al.
Publicado: (2016)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production
por: Karabon, Lidia, et al.
Publicado: (2021)

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
por: Grzasko, Norbert, et al.
Publicado: (2021)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis
por: Williams, Cayman, et al.
Publicado: (2022)

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds
por: Li, Wei, et al.
Publicado: (2019)

The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80
por: Kennedy, Alan, et al.
Publicado: (2023)

Variation in the gene encoding the co-inhibitory molecule BTLA is associated with survival in patients treated for clear cell renal carcinoma – results of a prospective cohort study
por: Tupikowski, Krzysztof, et al.
Publicado: (2021)

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
por: Dhodapkar, Kavita, et al.
Publicado: (2014)

Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report
por: Yano, Mitsutake, et al.
Publicado: (2018)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
por: Werner, Jan-Michael, et al.
Publicado: (2019)

Clonality of CD4(+) Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
por: Arakawa, Akiko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ebj3haon97tt6h8l4i8gkd39tb